Federal Register Notice: FDA has determined the regulatory review period for Eli Lilly’s Eraxis is 3,476 days for the purpose of patent extension. Eraxis is indicated for treating the fungal infections Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis), and esophageal candidiasis. To view this notice, click here.
